Sanda MG - Search Results

1

The prostate health index selectively identifies clinically significant prostate cancer.

Loeb S, Sanda MG, Broyles DL, Shin SS, Bangma CH, Wei JT, Partin AW, Klee GG, Slawin KM, Marks LS, van Schaik RH, Chan DW, Sokoll LJ, Cruz AB, Mizrahi IA, Catalona WJ. Loeb S, et al. Among authors: sanda mg. J Urol. 2015 Apr;193(4):1163-9. doi: 10.1016/j.juro.2014.10.121. Epub 2014 Nov 15. J Urol. 2015. PMID: 25463993 Free PMC article.

2

Gene therapy for urologic cancer.

Sanda MG, Simons JW. Sanda MG, et al. Urology. 1994 Oct;44(4):617-24. doi: 10.1016/s0090-4295(94)80075-8. Urology. 1994. PMID: 7524239 Review. No abstract available.

3

Concordance rates for benign prostatic disease among twins suggest hereditary influence.

Partin AW, Page WF, Lee BR, Sanda MG, Miller RN, Walsh PC. Partin AW, et al. Among authors: sanda mg. Urology. 1994 Nov;44(5):646-50. doi: 10.1016/s0090-4295(94)80197-5. Urology. 1994. PMID: 7526523 Free article.

4

Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy.

Partin AW, Piantadosi S, Sanda MG, Epstein JI, Marshall FF, Mohler JL, Brendler CB, Walsh PC, Simons JW. Partin AW, et al. Among authors: sanda mg. Urology. 1995 May;45(5):831-8. doi: 10.1016/S0090-4295(99)80091-0. Urology. 1995. PMID: 7538245

5

Demonstration of a rational strategy for human prostate cancer gene therapy.

Sanda MG, Ayyagari SR, Jaffee EM, Epstein JI, Clift SL, Cohen LK, Dranoff G, Pardoll DM, Mulligan RC, Simons JW. Sanda MG, et al. J Urol. 1994 Mar;151(3):622-8. doi: 10.1016/s0022-5347(17)35032-2. J Urol. 1994. PMID: 8308972 Free article.

6

Histopathologic characterization of hereditary benign prostatic hyperplasia.

Doehring CB, Sanda MG, Partin AW, Sauvageot J, Juo H, Beaty TH, Epstein JI, Hill G, Walsh PC. Doehring CB, et al. Among authors: sanda mg. Urology. 1996 Oct;48(4):650-3. doi: 10.1016/S0090-4295(96)00329-9. Urology. 1996. PMID: 8886078 Free article.

7

Clinical and biological characteristics of familial benign prostatic hyperplasia.

Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, Stoner E, Walsh PC. Sanda MG, et al. J Urol. 1997 Mar;157(3):876-9. J Urol. 1997. PMID: 9072590

8

Longitudinal cohort analysis of lethal prostate cancer progression in transgenic mice.

Hsu CX, Ross BD, Chrisp CE, Derrow SZ, Charles LG, Pienta KJ, Greenberg NM, Zeng Z, Sanda MG. Hsu CX, et al. Among authors: sanda mg. J Urol. 1998 Oct;160(4):1500-5. J Urol. 1998. PMID: 9751403

9

Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer.

Sanda MG, Smith DC, Charles LG, Hwang C, Pienta KJ, Schlom J, Milenic D, Panicali D, Montie JE. Sanda MG, et al. Urology. 1999 Feb;53(2):260-6. doi: 10.1016/s0090-4295(98)00539-1. Urology. 1999. PMID: 9933036

10

Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, Weber CE, Baccala AA, Goemann MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC, Partin AW, Carter HB, Piantadosi S, Marshall FF, Nelson WG. Simons JW, et al. Among authors: sanda mg. Cancer Res. 1999 Oct 15;59(20):5160-8. Cancer Res. 1999. PMID: 10537292 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

213 results

Search Page